Slide 1: Second Quarter 2018: Trusted by the Life Sciences Industry
Second Quarter 2018 Trusted by the Life Sciences Industry 1
Slide 2: Safe Harbor – Forward Looking Statements
Safe Harbor – Forward Looking Statements This presentation contains certain forward-looking statements that involve risks and uncertainties. Such forward-looking statements include statements regarding attempts to identify new strategic opportunities which may include a strategic transaction, plans
Slide 3: Quarterly Overview
Quarterly Overview Leading temperature-controlled logistics solutions provider for the life sciences industry with a focus on Business description the regenerative medicine market (e.g., CAR-T) Clients Pharmaceutical and biotechnology companies (e.g., Novartis, Gilead/Kite(a), Atara, Zoetis etc.) Ma
Slide 4: Global Logistics Centers & Volume Heat Maps
Global Logistics Centers & Volume Heat Maps 866 Global Regenerative Medicine Companies (up from 672 in 2016) – 466 North America, 235 Europe and Israel, 127 Asia, and 16 RoW. May, 2018 Gilead announced a new YescartaTM manufacturing facility would be built in Amsterdam, Netherlands. July, 2018 Novar
Slide 5: Global Transportation Partnerships
Global Transportation Partnerships Cryoport’s solutions have global reach through shipping agreements with FedEx, UPS, DHL, and World Courier FedEx® Deep Frozen Shipping Solution powered by Cryoport® 5
Slide 6: Clinical Trials Drive Revenue Growth in Biopharma
Clinical Trials Drive Revenue Growth in Biopharma 22 new clinical trials (net) added in Q2-2018; 86 clinical trials (net) added since Q2-2017; 34 Phase III 258 34 110 114 6
Slide 7: Primary Target Market: Regenerative Therapy
Primary Target Market: Regenerative Therapy Industry inflection point: Ph. I: 324 Commercialization has begun (261 in 2016) Novartis’ CAR-T drug, KymriahTM , 977 (192 in 2015) Ph. II: 560 approved in August 2017 and Gilead/Kite therapy, Yescarta™, approved in October 2017 Clinical trials underway(a)
Slide 8: Chain of Compliance Logistics Management
Chain of ComplianceTM Logistics Management CHAIN of CUSTODY CHAIN of CONDITION CHAIN of IDENTITY CHAIN of COMPLIANCETM Traceability of the Custody Traceability of the Condition Traceability of the Identity Traceability of the Equipment of each Client’s or of each Client’s of each Client’s or and Pro
Slide 9: Current FDA Approved RMAT Designations
Current FDA Approved RMAT Designations Company Product Indication Website Year Asterias Biotherapeutics AST-OPC1 Spinal Cord www.asteriasbiotherapeutics.com 2017 Athersys Multistem Ischemic Stroke www.athersys.com 2017 Bluebird Bio Lentiglobin Sickle Cell www.bluebirdbio.com 2017 Cellvation CEVA101
Slide 10: Adoptive Cellular Therapy: Immuno-Oncology Landscape
Adoptive Cellular Therapy: Immuno-Oncology Landscape Source – Wells Fargo Securities Conference, November 2017 10
Slide 11: Novartis – Kymriah Ramp Continues
Novartis – KymriahTM Ramp Continues Second indication of KymriahTM for adult r/r DLBCL approved in Q2 2018 Received positive CHMP opinion for both r/r pediatric & young adult ALL and r/r DLBCL in Q2 $16 million Q2 2018 commercial revenue for KymriahTM Six additional active clinical trials Manufactur
Slide 12: Gilead – Yescarta Ramp Builds
Gilead – Yescarta™ Ramp Builds Yescarta™ approved in U.S. in October 2017 Received positive CHMP opinion for r/r DLBCL in Q2 and European approval anticipated in Q3 2018. $68 million in net commercial YescartaTM revenues in Q2 2018 61 cancer centers authorized as of June 30, 2018 with access to appr
Slide 13: CryoStork for Reproductive Medicine
CryoStork℠ for Reproductive Medicine New: CryoStork℠ Insurance Providing Expectant Parents with Peace of Mind Multi-tiered insurance solution to be offered through Cryoport’s network of ~400 fertility clinics 13
Slide 14: Leveraging the Scalable Business Model
Leveraging the Scalable Business Model Continuing strong double-digit growth in revenue, year-over-year and sequentially Net revenue for the six months ended June 30, 2018 Gross margin for the six months ended June 30, 2018 vs. prior year ($mm) vs. prior year (%) $10.0 $8.7M + 7PP 60.0% 54% 54.3% +
Slide 15: Quarterly Revenue Trends
Quarterly Revenue Trends Continued quarterly revenue growth fueled by revenue expansion from existing clients and new client acquisitions $4.6M $4.0M $3.3M $2.9M $3.0M Q2-2018 over Q2-2017 growth: 58.6% Sequential growth: 15.0% 15
Slide 16: Quarterly Revenue Trends (cont'd)
Quarterly Revenue Trends (cont’d) Biopharma growth continues to be driven by ramp in clinical trials supported and commencement of revenue from the support of commercials therapy launches Q2-2018 over Q2-2017 growth: +72.6% +17.2% +6.5% 16
Slide 17: Financial Summary
Financial Summary Statements of Operations Data: (in thousands) 2015 2016 2017 Q2-2017 Q2-2018 QoQ growth % Net Revenues $ 5,525 $ 7,679 $ 11,954 $ 2,917 $ 4,627 58.6% Biopharma 3,364 5,302 9,113 2,229 3,849 72.6% Animal Health 869 845 1,135 262 279 6.5% Reprodcutive Medicine 1,292 1,532 1,707 426 5
Slide 18: Added to Russell 2000 and Russell 3000 Index
Added to Russell 2000® Index and Russell 3000® Index 16 Share Price ($) 14 Cryoport added to the Russell 2000 and Russell 3000 Indexes on June 25 th 12 Russell US Indexes widely used by investment managers and institutional investors as the building blocks of a broad range of financial products, suc
Slide 19: Conclusion
Conclusion Large & Rapidly Developing Market for Temperature Controlled Logistics for the Life Sciences Established Brand with Impressive Revenue Full Cryogenic Logistics Growth Solutions Suite Strategically Positioned Diversified, Growing, with Leading Clients in Sticky Client Base the Life Science
Slide 20: Financial Highlights: Q2-2018
Financial Highlights: Q2-2018 Revenue Biopharma Supporting revenue 34 Phase III $4.6M 258 clinical trials trials up 59% up 73% Reproductive Gross Margin $446,00 revenue from Medicine commercial agreements 54% up 17% up 6.0PP Strong embedded growth Opex up 53% in support of with existing clients expe